Acadia Pharmaceuticals director Garofalo sells $41,560 in stock

Published 03/09/2025, 23:48
Acadia Pharmaceuticals director Garofalo sells $41,560 in stock

Director Elizabeth A. Garofalo of Acadia Pharmaceuticals Inc (NASDAQ:ACAD), a $4.3 billion market cap company that has delivered an impressive 57% return over the past year, sold 1,600 shares of common stock on September 2, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at weighted average prices ranging from $25.97 to $25.991, for a total transaction value of $41,560. The transaction occurred near ACAD’s 52-week high of $26.65, with the stock showing strong momentum. InvestingPro analysis reveals the company maintains excellent financial health with an overall score of 3.67/5, suggesting robust fundamentals.

Following the transaction, Garofalo directly owns 25,382 shares of Acadia Pharmaceuticals. According to InvestingPro, the company shows promising potential with 13 additional key insights available to subscribers, including detailed valuation metrics and growth forecasts. Get access to the comprehensive Pro Research Report for deeper analysis of ACAD’s market position and future prospects.

In other recent news, Acadia Pharmaceuticals reported its second-quarter financial results, with Nuplazid sales hitting $168.5 million, aligning with consensus expectations. The company also saw Daybue sales of $96.1 million, surpassing consensus estimates. Following these results, Mizuho raised its price target for Acadia Pharmaceuticals to $24 from $23, maintaining a Neutral rating. Stifel also increased its price target to $24 from $18, citing solid execution of Nuplazid and Daybue, while maintaining a Hold rating. Citizens JMP went further, raising its price target to $38 from $37, noting that the financial results exceeded both its and consensus estimates. In personnel news, Acadia Pharmaceuticals appointed Konstantina "Tina" Katcheves as Senior Vice President, Chief Business and Strategy Officer. Katcheves will lead business development and corporate strategy, reporting directly to CEO Catherine Owen Adams. These developments highlight recent strategic and financial activities within the company.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.